Related Experiment Video

Updated: Mar 12, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer

Pascale Tomasini1, Preet Walia1, Catherine Labbe1

  • 1Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

The Oncologist
|November 4, 2016
PubMed

Insights

Targeting KRAS mutations in non-small cell lung cancer (NSCLC) offers new therapeutic avenues. Research explores direct KRAS inhibition and downstream effectors for KRAS-mutant NSCLC treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a leading cause of cancer mortality globally.
  • Personalized therapy for NSCLC has advanced, targeting molecular aberrations like EGFR and ALK.
  • KRAS mutations occur in ~30% of lung adenocarcinomas, presenting a significant therapeutic target.

Purpose of the Study:

  • To review the KRAS pathway in lung cancer.
  • To explore emerging therapeutic strategies targeting KRAS mutations in NSCLC.

Main Methods:

  • Literature review of KRAS pathway and targeted therapies in NSCLC.
  • Analysis of current and potential therapeutic approaches for KRAS-mutant NSCLC.

Main Results:

  • KRAS is a frequent target in lung adenocarcinoma.
  • Multiple therapeutic strategies are under investigation, including direct KRAS inhibition and targeting downstream effectors.
  • No KRAS-targeted therapies are currently approved, but several show promise.

Conclusions:

  • KRAS-mutant NSCLC represents a critical area for therapeutic development.
  • Targeted inhibition of KRAS or its pathway components may significantly improve outcomes for NSCLC patients.
  • Future research and clinical trials are essential to validate these emerging therapies.
Keywords:
KRASMEKNon-small cell lung cancerPathwaySelumetinibTargetTrametinib

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

496
Detection of Lung Tumor Progression in Mice by Ultrasound Imaging04:43

Detection of Lung Tumor Progression in Mice by Ultrasound Imaging

Published on: February 27, 2020

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K